International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43

Phase IV

on behalf of the EORTC Quality of Life and the EORTC Head and Neck Cancer Groups

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.

Original languageEnglish
JournalHead and Neck
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Head and Neck Neoplasms
Quality of Life
Reproducibility of Results
Statistical Factor Analysis
Survivors
Neck
Head
Therapeutics
Surveys and Questionnaires

Keywords

  • chemoradiation
  • head and neck cancer
  • multimodal therapies
  • quality of life
  • validation

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43 : Phase IV. / on behalf of the EORTC Quality of Life and the EORTC Head and Neck Cancer Groups.

In: Head and Neck, 01.01.2019.

Research output: Contribution to journalArticle

@article{2aa2f803d05343fe961ec535bcb77685,
title = "International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV",
abstract = "Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.",
keywords = "chemoradiation, head and neck cancer, multimodal therapies, quality of life, validation",
author = "{on behalf of the EORTC Quality of Life and the EORTC Head and Neck Cancer Groups} and Susanne Singer and Amdal, {Cecilie Delphin} and Eva Hammerlid and Tomaszewska, {Iwona M.} and {Castro Silva}, Joaquim and Hisham Mehanna and Marcos Santos and Johanna Inhestern and Christine Brannan and Noam Yarom and Amy Fullerton and Monica Pinto and Arraras, {Juan I.} and Naomi Kiyota and Pierluigi Bonomo and Sherman, {Allen C.} and Ingo Baumann and Razvan Galalae and {Fernandez Gonzalez}, Loreto and Ourania Nicolatou-Galitis and Zeinab Abdel-Hafeez and Judith Raber-Durlacher and Claudia Schmalz and Paola Zotti and Andreas Boehm and Dirk Hofmeister and {Krejovic Trivic}, Sanja and Suat Loo and Chie, {Wei Chu} and Kristin Bjordal and {Brokstad Herlofson}, Bente and Vincent Gr{\'e}goire and Lisa Licitra",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hed.25609",
language = "English",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43

T2 - Phase IV

AU - on behalf of the EORTC Quality of Life and the EORTC Head and Neck Cancer Groups

AU - Singer, Susanne

AU - Amdal, Cecilie Delphin

AU - Hammerlid, Eva

AU - Tomaszewska, Iwona M.

AU - Castro Silva, Joaquim

AU - Mehanna, Hisham

AU - Santos, Marcos

AU - Inhestern, Johanna

AU - Brannan, Christine

AU - Yarom, Noam

AU - Fullerton, Amy

AU - Pinto, Monica

AU - Arraras, Juan I.

AU - Kiyota, Naomi

AU - Bonomo, Pierluigi

AU - Sherman, Allen C.

AU - Baumann, Ingo

AU - Galalae, Razvan

AU - Fernandez Gonzalez, Loreto

AU - Nicolatou-Galitis, Ourania

AU - Abdel-Hafeez, Zeinab

AU - Raber-Durlacher, Judith

AU - Schmalz, Claudia

AU - Zotti, Paola

AU - Boehm, Andreas

AU - Hofmeister, Dirk

AU - Krejovic Trivic, Sanja

AU - Loo, Suat

AU - Chie, Wei Chu

AU - Bjordal, Kristin

AU - Brokstad Herlofson, Bente

AU - Grégoire, Vincent

AU - Licitra, Lisa

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.

AB - Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.

KW - chemoradiation

KW - head and neck cancer

KW - multimodal therapies

KW - quality of life

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=85059916248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059916248&partnerID=8YFLogxK

U2 - 10.1002/hed.25609

DO - 10.1002/hed.25609

M3 - Article

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

ER -